Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

476.98 +7.71 (+1.64%)
Streaming Delayed Price Updated: 2:13 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
News headline image
4 Healthcare Stocks to Buy Now ↗
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity ↗
 
Via Benzinga
News headline image
The Smartest Growth Stock to Buy With $500 Right Now ↗
Vertex isn't your run-of-the-mill biotech stock. 
Via The Motley Fool
Topics Economy
News headline image
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?
Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This... 
Via StockStory
Topics Stocks
News headline image
Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500 ↗
Tariffs aren't likely to weigh on growth at these companies. 
Via The Motley Fool
Topics Government Stocks World Trade
News headline image
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
1 Healthcare Stock with Exciting Potential and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
News headline image
2 Beaten-Down Stocks Primed for a Comeback ↗
The market is sleeping on these stocks, but you don't have to. 
Via The Motley Fool
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' ↗
Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX). 
Via Benzinga
Topics ETFs Stocks
News headline image
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
What Does the Market Think About Vertex Pharmaceuticals Inc? ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
2 S&P 500 Stocks to Research Further and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
5 Top Stocks to Buy in October ↗
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
Via The Motley Fool
Topics Stocks
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗
Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
My 3 Favorite Stocks to Buy Right Now ↗
Uncertainty is in the air. But these stocks inspire confidence. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗
Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation. 
Via Chartmill
News headline image
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
News headline image
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
News headline image
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
News headline image
2 Growth Stocks to Buy and Hold Forever ↗
Look beyond the recent headwinds these two have faced. 
Via The Motley Fool
Topics World Trade
News headline image
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals ↗
Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.